Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

Journal of Clinical Oncology

Volumn 26, Issue 4, 2008, Pages 527-534

  Korn, Edward L ^a   Liu, Ping Yu ^b   Lee, Sandra J ^b   Chapman, Judith Anne W ^b   Niedzwiecki, Donna ^b   Suman, Vera J ^b   Moon, James ^b   Sondak, Vernon K ^b   Atkins, Michael B ^b   Eisenhauer, Elizabeth A ^b   Parulekar, Wendy ^b   Markovic, Svetomir N ^b   Saxman, Scott ^b   Kirkwood, John M ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CLINICAL STUDY; DISEASE FREE SURVIVAL; FEMALE; GROUPS BY AGE; HUMAN; INFORMATION RETRIEVAL; KAPLAN MEIER METHOD; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTATIC STAGE IV; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PATIENT CODING; PERFORMANCE; PHASE 2 COOPERATIVE GROUP TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUALITY CONTROL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; UNIVARIATE ANALYSIS; VISCERAL METASTASIS; BRAIN TUMOR; META ANALYSIS; METASTASIS; METHODOLOGY; MORTALITY; PHASE 2 CLINICAL TRIAL; SAMPLE SIZE; SKIN TUMOR; STANDARD; STATISTICS; SURVIVAL; SURVIVAL RATE;

BENCHMARKING; BRAIN NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; MELANOMA; META-ANALYSIS AS TOPIC; MULTIVARIATE ANALYSIS; PROGNOSIS; RESEARCH DESIGN; SAMPLE SIZE; SKIN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 39149104690     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.7837     Document Type: Article

References (29)

1. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
2. Taylor JMG, Braun TM, Li Z: Comparing an experimental agent to a standard agent: Relative merits of a one-am or randomized two-arm Phase II design. Clin Trials 3:335-348, 2006
3. Margolin KA, Liu PY, Flaherty LE, et al: Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A Southwest Oncology Group study. J Clin Oncol 16:664-669, 1998
4. Balch CM, Buzaid AC, Soong S-J, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001
5. Panageas K, Ben-Porat L, Dickler MN, et al: When you look matters: The effect of assessment schedule on progression-free survival. J Natl Cancer Inst 99:428-432, 2007
6. Einhorn LH, Burgess MA, Vallejos C, et al: Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res 34:1995-2004, 1974
7. Amer MH, Al-Sarraf M, Vaitkevicius VK: Clinical presentation, natural history and prognostic factors in advanced malignant melanoma. Surg Gynecol Obstet 149:687-692, 1979
8. Rampen F: Malignant melanoma: Sex differences in survival after evidence of distant metastases. Br J Cancer 42:52-57, 1980
9. Presant CA, Bartolucci AA: Prognostic factors in malignant melanoma: The Southeastern Cancer Study Group experience. Cancer 49:2192-2196, 1982
10. Balch CM, Soong S, Murad TM, et al: A multifactorial analysis of melanoma: IV. Prognostic factors in 200 melanoma patients with distant metastases. J Clin Oncol 1:126-134, 1983
11. Heimdal K, Hannisdal E, Gundersen S: Regression analyses of prognostic factors in metastatic malignant melanoma. Eur J Cancer Clin Oncol 25:1219-1223, 1989
12. Sirott MN, Bajorin DF, Wong GYC, et al: Prognostic factors in patients with metastatic malignant melanoma. Cancer 72:3091-3098, 1993
13. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193-201, 1995
14. Brand CU, Ellwanger U, Stroebel W, et al: Prolonged survival of 2 years or longer for patients with disseminated melanoma. Cancer 79:2345-2353, 1997
15. Falkson CI, Falkson HC: Prognostic factors in metastatic malignant melanoma. Oncology 55:59-64, 1998
16. Keilholz U, Conradt C, Legha SS, et al: Results of interleukin-2-based treatment in advanced melanoma: A case record-based analysis of 631 patients. J Clin Oncol 16:2921-2929, 1998
17. Eton O, Legha SS, Moon TE, et al: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16:1103-1111, 1998
18. Ryan L, Kramar A, Borden E: Prognostic factors in metastatic melanoma. Cancer 71:2995-3005, 1993
19. Manola J, Atkins M, Ibrahim J, et al: Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18:3782-3793, 2000
20. Unger JM, Flaherty LE, Liu PY, et al: Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer 91:1148-1155, 2001
21. Balch CM, Soong S, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001
22. Deichmann M, Benner A, Bock M, et al: S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from non-progressive American Joint Committe on Cancer stage IV melanoma. J Clin Oncol 17:1891-1896, 1999
23. Van Glabbeke M, Verwij J, Judson I, et al: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549, 2002
24. Francart J, Legrand C, Sylvester R, et al: Progression-free survival rate as primary endpoint for phase II cancer clinical trials: Application to mesothelioma - The EORTC Lung Cancer Group. J Clin Oncol 24:3007-3012, 2006
25. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
26. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005
27. Kish JA, Kopecky K, Samson MK, et al: Evaluation of fludarabine phosphate in malignant melanoma. Invest New Drugs 9:105-108, 1991
28. Amato DA, Bruckner H, Guerry D, et al: Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma. Invest New Drugs 5:293-297, 1987
29. Breslow NE: Analysis of survival data under the proportional hazards model. Int Stat Rev 43:45-58, 1975